JP2023538278A5 - - Google Patents
Info
- Publication number
- JP2023538278A5 JP2023538278A5 JP2023507920A JP2023507920A JP2023538278A5 JP 2023538278 A5 JP2023538278 A5 JP 2023538278A5 JP 2023507920 A JP2023507920 A JP 2023507920A JP 2023507920 A JP2023507920 A JP 2023507920A JP 2023538278 A5 JP2023538278 A5 JP 2023538278A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- asthma
- subject
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061226P | 2020-08-05 | 2020-08-05 | |
| US63/061,226 | 2020-08-05 | ||
| US202163136933P | 2021-01-13 | 2021-01-13 | |
| US63/136,933 | 2021-01-13 | ||
| US202163147024P | 2021-02-08 | 2021-02-08 | |
| US63/147,024 | 2021-02-08 | ||
| US202163174938P | 2021-04-14 | 2021-04-14 | |
| US63/174,938 | 2021-04-14 | ||
| PCT/US2021/044719 WO2022031956A1 (en) | 2020-08-05 | 2021-08-05 | Use of dexpramipexole for the treatment of moderate to severe asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538278A JP2023538278A (ja) | 2023-09-07 |
| JP2023538278A5 true JP2023538278A5 (enExample) | 2024-08-13 |
Family
ID=80115688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507920A Pending JP2023538278A (ja) | 2020-08-05 | 2021-08-05 | 中等度から重度の喘息の治療におけるデクスプラミペキソールの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20220040154A1 (enExample) |
| EP (1) | EP4192453A4 (enExample) |
| JP (1) | JP2023538278A (enExample) |
| KR (1) | KR20230067604A (enExample) |
| CN (1) | CN116419746A (enExample) |
| AU (1) | AU2021322255A1 (enExample) |
| CA (1) | CA3186844A1 (enExample) |
| CL (1) | CL2023000296A1 (enExample) |
| IL (1) | IL300357A (enExample) |
| MX (1) | MX2023001140A (enExample) |
| WO (1) | WO2022031956A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260119B (zh) * | 2022-07-26 | 2023-02-10 | 山东京卫制药有限公司 | 一种普拉克索昔萘酸盐及其药物缓释制剂 |
| KR102985795B1 (ko) | 2023-06-29 | 2026-07-06 | 재단법인 아산사회복지재단 | 천식의 분류를 위한 바이오마커 및 이의 용도 |
| WO2025137230A1 (en) * | 2023-12-20 | 2025-06-26 | Areteia Therapeutics, Inc. | Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma |
| WO2025137498A1 (en) * | 2023-12-20 | 2025-06-26 | Areteia Therapeutics, Inc. | Matrix tablets of dexpramipexole and methods of manufacturing and use thereof |
| WO2025240942A1 (en) * | 2024-05-17 | 2025-11-20 | Areteia Therapeutics, Inc. | Use of dexpramipexole for the treatment of eosinophilic copd |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7741490B2 (en) * | 2004-03-19 | 2010-06-22 | Dipharma S.P.A. | Intermediates for the preparation of pramipexole |
| KR20100134702A (ko) * | 2008-03-28 | 2010-12-23 | 글락소스미스클라인 엘엘씨 | 치료 방법 |
| WO2013034173A1 (en) * | 2011-09-06 | 2013-03-14 | Synthon Bv | Pramipexole extended release tablets |
| US9468630B2 (en) * | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| RS67279B1 (sr) * | 2013-07-12 | 2025-10-31 | Areteia Therapeutics Inc | Lečenje povišenih nivoa eozinofila i/ili bazofila |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| WO2017197360A1 (en) * | 2016-05-13 | 2017-11-16 | The Regents Of The University Of California | Airway mucus impaction |
-
2021
- 2021-08-05 MX MX2023001140A patent/MX2023001140A/es unknown
- 2021-08-05 US US17/395,059 patent/US20220040154A1/en not_active Abandoned
- 2021-08-05 WO PCT/US2021/044719 patent/WO2022031956A1/en not_active Ceased
- 2021-08-05 KR KR1020237007598A patent/KR20230067604A/ko active Pending
- 2021-08-05 AU AU2021322255A patent/AU2021322255A1/en active Pending
- 2021-08-05 IL IL300357A patent/IL300357A/en unknown
- 2021-08-05 CA CA3186844A patent/CA3186844A1/en active Pending
- 2021-08-05 EP EP21852896.6A patent/EP4192453A4/en active Pending
- 2021-08-05 JP JP2023507920A patent/JP2023538278A/ja active Pending
- 2021-08-05 CN CN202180068016.4A patent/CN116419746A/zh active Pending
-
2023
- 2023-01-30 CL CL2023000296A patent/CL2023000296A1/es unknown
- 2023-10-11 US US18/485,086 patent/US20240041841A1/en not_active Abandoned
- 2023-10-11 US US18/485,082 patent/US20240041840A1/en not_active Abandoned
-
2025
- 2025-09-25 US US19/340,207 patent/US20260021077A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buhl et al. | Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) | |
| Bateman et al. | Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma | |
| Battaglia et al. | Safety considerations of inhaled corticosteroids in the elderly | |
| Boulet et al. | Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma | |
| CN107073114B (zh) | 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘 | |
| Eastwood et al. | A randomized trial of a composite T2-biomarker strategy adjusting corticosteroid treatment in severe asthma: a post hoc analysis by sex | |
| Hozawa et al. | Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy | |
| Buhl et al. | Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma | |
| Bergmann et al. | Salmeterol/fluticasone propionate (50/250 µg) combination is superior to double dose fluticasone (500 µg) for the treatment of symptomatic moderate asthma | |
| Rubinfeld et al. | Formoterol Turbuhaler as reliever medication in patients with acute asthma | |
| CN116419746A (zh) | 右旋普拉克索用于治疗中度至重度哮喘的用途 | |
| Ohbayashi et al. | Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study | |
| Shi et al. | Efficacy of dupilumab in the treatment of COPD with type 2 inflammation: a real-world study | |
| van Schayck et al. | Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study | |
| JP2023538419A5 (enExample) | ||
| Higenbottam et al. | Comparison of nebulised budesonide and prednisolone in severe asthma exacerbation in adults | |
| Battaglia et al. | Erratum to: safety considerations of inhaled corticosteroids in the elderly | |
| US20230023935A1 (en) | Use of masitinib for the treatment of eosinophilic asthma | |
| WO2019053591A1 (en) | USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS | |
| Lemanske Jr | Choosing therapy for childhood asthma | |
| Chen et al. | Inhaled JAK Inhibitor GDC-0214 Reduces Exhaled Nitric Oxide in Patients with Mild Asthma | |
| Rigby | CPD: Chronic disease management: Triple therapy in COPD: The impact of impact | |
| Bayoumi-Ali et al. | Drugs That Act on the Respiratory Tract | |
| JP2007506768A (ja) | 肺疾患処置 | |
| Reti | Ventolin to Salamol--a crossover study in New Zealand |